You are here: Industry Insights > AbbVie

News List

Financial Report - Abbvie contractpharma
May 04, 2020
Global HUMIRA revenues were $4.7 billion, up 6% in the quarter.
AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML pharmaceutical-business-review
March 27, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA (venetoclax) in combination with azacitidine versus azacitidine in combination ...
AbbVie Announces Positive Results from VENCLEXTA, Azacitidine Combination for AML americanpharmaceuticalreview
March 26, 2020
AbbVie announced the VIALE-A (M15-656) trial of VENCLEXTA? (venetoclax) in combination with azacitidine versus azacitidine in combination ...
AbbVie, Allergan megamerger set for May close pharmatimes
March 23, 2020
AbbVie has released an update on its pending acquisition of Allergan, announcing that the companies have entered into a consent decree agreement with staff of the US Federal Trade Commission (FTC) regarding the deal.
Israel approves import of generic of AbbVie’s HIV drug for Covid-19 pharmaceutical-technology
March 23, 2020
Israel health ministry has approved the licensing of a generic version of AbbVie’s HIV drug Kaletra to treat Covid-19, as the cases in the country exceed 500.
AbbVie’s HIV drug combo shows no benefit in Covid-19 trial pharmaceutical-technology
March 20, 2020
A clinical trial in Covid-19 patients in China has yielded no therapeutic benefits with AbbVie’s HIV drug combination of lopinavir and ritonavir, marketed as Kaletra.
AbbVie Receives EC Approval of VENCLYXTO Regimen for Lymphocytic Leukemia americanpharmaceuticalreview
March 16, 2020
AbbVie announced the European Commission (EC) has approved VENCLYXTO? (venetoclax) in combination with obinutuzumab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) ...
AbbVie to test HIV drug for Covid-19 treatment pharmaceutical-technology
March 12, 2020
AbbVie has announced plans to evaluate HIV medicine Kaletra / Aluvia (lopinavir / ritonavir) as Covid-19 treatment.
EU Marketing Authorisation change for Maviret pharmatimes
March 10, 2020
The European Commission has granted AbbVie permission to change the Marketing Authorisation for Maviret (glecaprevir/pibrentasvir) to eight weeks of treatment.
European Commission Grants AbbVie Marketing Authorization for Shorter MAVIRET Treatment americanpharmaceuticalreview
March 09, 2020
AbbVie announced that the European Commission has approved a change to the marketing authorization for MAVIRET? (glecaprevir/pibrentasvir) to shorten once-daily treatment duration ...